Ovarian Cancer Drugs

Ovarian Cancer Drugs Market Outlook

The global Ovarian Cancer Drugs market is projected to reach USD 5.28 billion by 2035, expanding at a compound annual growth rate (CAGR) of approximately 7.2% from 2025 to 2035. This robust growth can be attributed to the increasing prevalence of ovarian cancer worldwide, along with advancements in drug development and personalized medicine. The heightened awareness of ovarian cancer symptoms among women is also contributing to earlier diagnoses, which in turn drives the demand for effective pharmacological treatments. Furthermore, the ongoing research and clinical trials focusing on novel therapeutic agents and combinations are expected to significantly enhance treatment efficacy and patient outcomes in the coming years. This burgeoning market presents lucrative opportunities for pharmaceutical companies specializing in oncology, thereby fostering collaborative efforts between research institutions and industry leaders.

Growth Factor of the Market

Several factors are catalyzing the growth of the Ovarian Cancer Drugs market. One primary driver is the rising incidence of ovarian cancer attributed to genetic predisposition and lifestyle choices, resulting in an increased need for effective treatment options. Additionally, the continuous evolution in drug formulations, including targeted therapies, has enhanced the treatment landscape, providing patients with more personalized and effective care. Moreover, regulatory agencies worldwide are fast-tracking the approval process for innovative therapies, allowing for quicker access to new drugs for patients. The growing focus on early detection and screening methods has also pushed the market, as more women are diagnosed at earlier stages when treatment is likely to be more effective. Furthermore, the surge in funding from both public and private sectors for ovarian cancer research is fostering new developments, thus propelling market growth.

Key Highlights of the Market

• The global market for ovarian cancer drugs is anticipated to reach USD 5.28 billion by 2035.
• CAGR of approximately 7.2% from 2025 to 2035.
• Increasing prevalence of ovarian cancer is driving demand for various drug classes.
• Significant advancements in drug development and personalized medicine are enhancing treatment efficacy.
• Fast-tracked regulatory approvals for innovative therapies are improving patient access to new treatments.

By Drug Class

Platinum-Based Drugs:

Platinum-based drugs, such as cisplatin and carboplatin, have long been the cornerstone of ovarian cancer treatment. These agents function by interfering with DNA replication in cancer cells, effectively inducing cell death. Their usage is particularly prominent in the initial treatment regimen for advanced ovarian cancer and is often combined with other agents to enhance therapeutic efficacy. The growing recognition of their effectiveness in neoadjuvant chemotherapy settings is further solidifying their relevance in treatment protocols. Their widespread acceptance among oncologists is also propelled by clinical trials demonstrating significant survival benefits, making them a preferred choice for therapy. The market for platinum-based drugs is expected to remain robust, even with the emergence of novel therapeutic options, due to their established efficacy and safety profiles.

PARP Inhibitors:

Poly(ADP-ribose) polymerase (PARP) inhibitors have gained significant attention in the treatment of ovarian cancer, particularly for patients with BRCA mutations. These drugs work by exploiting the cancer cell's inability to repair DNA damage, leading to cell death. The introduction of pivotal PARP inhibitors such as olaparib and niraparib has revolutionized treatment strategies, allowing for maintenance therapies that improve progression-free survival. As more clinical studies validate their effectiveness, the demand for PARP inhibitors is projected to surge, further supported by ongoing research into their combination with other therapeutic modalities. The significant potential for expansion in usage across various cancer types also contributes to a promising growth outlook for this drug class in the ovarian cancer market.

Angiogenesis Inhibitors:

Angiogenesis inhibitors, including drugs like bevacizumab, play a critical role in ovarian cancer treatment by blocking the formation of new blood vessels, thereby restricting tumor growth and metastasis. This class of drugs targets vascular endothelial growth factor (VEGF), a key regulator in angiogenesis. The efficacy of angiogenesis inhibitors in combination with chemotherapy has been established through numerous clinical trials, which demonstrate improved outcomes in advanced ovarian cancer patients. As a result, these agents are frequently integrated into treatment regimens for recurrent disease. The growing emphasis on targeted therapies and personalized medicine is expected to bolster the market for angiogenesis inhibitors, particularly as more clinical studies explore their use in combination with other therapeutic options.

PD-L1 Inhibitors:

PD-L1 inhibitors are part of the immune checkpoint inhibitors class that aims to enhance the body’s immune response against cancer cells. Drugs like pembrolizumab are designed to inhibit the interaction between PD-1 on immune cells and PD-L1 on cancer cells, thereby promoting T-cell activation and anti-tumor response. Although still in the early stages of research for ovarian cancer, preliminary studies indicate that these agents can potentially improve outcomes, particularly for patients with advanced disease. The market for PD-L1 inhibitors is poised for growth as ongoing studies continue to demonstrate their safety and efficacy and as the medical community increasingly recognizes the importance of immunotherapy in cancer treatment.

Others:

This category encompasses a range of emerging therapies and drug classes that are currently under investigation or have recently entered the market. These may include novel small molecules, gene therapies, and other immunotherapeutics that target specific pathways involved in ovarian cancer progression. The diversity within this segment reflects the ongoing innovation in the field of oncology, as researchers explore various mechanisms to combat this complex disease. While currently smaller in market share compared to established classes, the ‘Others’ segment is expected to see significant growth as more products gain approval and clinical validation, thus enhancing treatment options available for ovarian cancer patients.

By Administration

Oral:

The oral administration of ovarian cancer drugs offers several advantages, including convenience and improved patient compliance. Patients often prefer oral medications due to their ease of use compared to intravenous therapies, which can require more frequent hospital visits and longer administration times. Notably, several effective therapies, such as PARP inhibitors, are available in oral formulations, making them a popular choice for maintenance treatments. The increasing incidence of outpatient treatment settings further boosts the demand for oral medications, allowing patients to manage their treatment regimens more flexibly. As more drugs transition to oral formulations, this segment of the market is expected to grow, providing new options for patients seeking effective yet manageable treatment pathways.

Injectable:

Injectable medications continue to be a primary mode of administration in the treatment of ovarian cancer, especially for therapies that require immediate systemic exposure or rapid action, such as platinum-based drugs and angiogenesis inhibitors. These drugs are typically administered in clinical settings, often as part of combination therapies. The efficacy of injectable formulations in achieving higher concentrations of the drug in the bloodstream contributes to their widespread usage, particularly in acute treatment settings. Moreover, advances in injection technology, such as the development of auto-injectors and pre-filled syringes, are enhancing patient convenience and adherence. The injectable segment of the ovarian cancer drugs market is likely to remain strong, driven by the need for effective treatment in more advanced stages of the disease.

By Distribution Channel

Hospitals:

Hospitals remain the primary distribution channel for ovarian cancer drugs, largely due to the acute nature of the disease and the need for comprehensive care involving multidisciplinary teams. These institutions are equipped with the necessary resources, including trained healthcare professionals and advanced medical technologies, to manage complex treatment regimens. Additionally, hospitals often participate in clinical trials that provide access to cutting-edge therapies, which can further enhance treatment options for patients. The growing focus on hospital-based oncology services and the rise in inpatient treatments for advanced stages of ovarian cancer are expected to bolster the market share of the hospital distribution channel significantly in the coming years.

Cancer Treatment Centers:

Cancer treatment centers have emerged as critical distribution channels for ovarian cancer drugs, providing specialized care tailored to the needs of oncology patients. These centers typically offer a comprehensive range of services, including chemotherapy, radiation therapy, and supportive care, all in a focused environment. The growing trend towards centralized cancer care is driving the establishment of more dedicated cancer treatment facilities that can administer advanced therapies efficiently. As patients increasingly seek out specialized services for their cancer treatment, the market presence of cancer treatment centers is expected to expand, further solidifying their role in the distribution of ovarian cancer medications.

Retail Pharmacies:

Retail pharmacies are becoming increasingly significant in the distribution of ovarian cancer drugs, particularly for oral medications and maintenance therapies. As the healthcare landscape evolves, many patients are looking for convenient options to obtain their medications without having to visit a hospital or cancer center constantly. Retail pharmacies provide an accessible alternative, particularly for patients managing their ongoing treatments. Additionally, with the integration of telehealth services, pharmacists can offer valuable guidance and support for patients undergoing ovarian cancer treatment. The growth of retail pharmacies in the distribution landscape is poised to increase as more patients prefer to fill their prescriptions in community settings that offer personalized care.

Online Pharmacies:

The rise of online pharmacies is transforming the way patients access ovarian cancer drugs, offering a convenient and often cost-effective alternative to traditional distribution channels. With the increasing adoption of e-commerce and digital health solutions, many patients can now order their medications online and receive them at their doorstep. This trend is particularly appealing for individuals who may face mobility challenges or live in remote areas with limited access to pharmacies. Online pharmacies often provide detailed information and support for patients, thereby enhancing medication adherence. As the digital landscape continues to evolve, the online pharmacy segment is expected to gain a more prominent role in the distribution of ovarian cancer drugs.

By Mechanism of Action

DNA Damage Response:

Drugs that target DNA damage response mechanisms play a pivotal role in treating ovarian cancer by exploiting the cancer cells' inherent vulnerabilities. These therapies work by inducing DNA damage or preventing the repair of DNA breaks, thereby leading to cell death. Notable examples include platinum-based agents and PARP inhibitors, both of which effectively disrupt the cancer cell's ability to manage and repair DNA lesions. The effectiveness of these therapies is particularly pronounced in tumors with specific genetic mutations, such as BRCA1/2, which are unable to efficiently repair DNA damage. As more research uncovers the intricacies of DNA damage response pathways, the market for these therapies is anticipated to grow, with the potential for novel combinations that enhance treatment outcomes.

Angiogenesis Inhibition:

Angiogenesis inhibition is a critical mechanism utilized by several ovarian cancer drugs, particularly those targeting the VEGF pathway. By disrupting the formation of new blood vessels that supply nutrients and oxygen to tumors, these therapies can effectively stifle tumor growth and progression. The clinical success of angiogenesis inhibitors like bevacizumab has established this mechanism as a cornerstone of treatment for recurrent ovarian cancer. Ongoing research into the intricacies of angiogenesis and the development of new agents targeting this pathway continue to expand the treatment landscape, presenting new opportunities for improving patient outcomes in ovarian cancer.

Immune Checkpoint Inhibition:

Immune checkpoint inhibitors represent an innovative mechanism of action that seeks to enhance the body’s immune response against ovarian cancer cells. By blocking proteins such as PD-1 and PD-L1, these agents reinvigorate T-cells to recognize and attack tumor cells more effectively. While still in the early stages of research for ovarian cancer, preliminary data shows potential for these treatments to produce durable responses in select patient populations. As ongoing clinical trials investigate the efficacy of immune checkpoint inhibitors in combination with other therapies, this approach may emerge as a viable treatment option, expanding the therapeutic arsenal against ovarian cancer.

Others:

This category encompasses various mechanisms of action that are under investigation or have been recently introduced in the market. These may include therapies targeting specific signaling pathways, novel immunotherapies, and next-generation drug candidates that act through different modes of action. The versatility within this ‘Others’ segment reflects the dynamic nature of cancer research, as scientists continuously explore new approaches to combat ovarian cancer. As clinical trials progress and more data become available, the market for these innovative therapies is expected to expand, providing additional options for patients and oncologists alike.

By Region

North America holds a significant share of the global ovarian cancer drugs market, with an estimated market valuation of USD 2.1 billion in 2025, capturing roughly 40% of the market. This is primarily driven by the high prevalence of ovarian cancer in the region, along with advanced healthcare infrastructure and substantial investments in oncology research. The presence of leading pharmaceutical companies and ongoing clinical trials further contribute to the region's dominance. Additionally, the increasing focus on personalized medicine and the rapid adoption of innovative therapies are expected to drive growth in North America at a CAGR of approximately 7.5% through 2035, solidifying its position as a key market for ovarian cancer treatments.

Europe is also a major player in the ovarian cancer drugs market, with a projected market size of USD 1.5 billion by 2035. The region benefits from a robust healthcare system, extensive research initiatives, and a favorable regulatory environment that promotes the development of new therapies. The European market is anticipated to grow at a CAGR of 6.8% from 2025 to 2035, driven by increasing awareness of ovarian cancer and the growing demand for advanced treatment options. Emerging markets within Asia Pacific are also witnessing growth, albeit at a slower pace, due to varying levels of healthcare access and awareness. The cumulative regional growth is expected to align with the global market trends, with North America and Europe leading the charge.

Opportunities

The ovarian cancer drugs market presents several opportunities for growth, particularly through the development of novel therapies and personalized medicine approaches. The increasing focus on targeted treatments tailored to individual patient profiles is gaining traction as more genetic and molecular insights are uncovered regarding ovarian cancer. This shift towards personalized medicine allows for more effective and less toxic treatment regimens, which can improve patient compliance and outcomes. Additionally, the advancements in diagnostic technologies are enabling earlier detection of ovarian cancer, thereby expanding the patient population that can benefit from these innovative therapies. Pharmaceutical companies that invest in research and development to capitalize on these trends are likely to experience significant market advantages and improved revenue potential.

Another promising opportunity lies in the expansion of clinical trials and studies aimed at exploring combination therapies. Utilizing a multi-faceted approach, where drugs with different mechanisms of action are used together, can enhance treatment efficacy and mitigate the chances of resistance. Collaborative partnerships between academic institutions, pharmaceutical companies, and healthcare providers can facilitate the design and execution of these trials, ultimately leading to the development of breakthrough therapies for ovarian cancer. Furthermore, increasing investment from government and nonprofit organizations in ovarian cancer research presents a favorable environment for innovation and growth, thereby contributing to a rapidly evolving treatment landscape.

Threats

Despite its growth prospects, the ovarian cancer drugs market is not without threats that could impede its progress. One major concern is the high cost associated with the development and production of innovative cancer therapies, which may limit patient access in certain regions and healthcare settings. As treatments become more specialized, the financial burden on healthcare systems could lead to disparities in access, particularly in low- and middle-income countries. Moreover, the increasing scrutiny from regulatory bodies concerning drug approvals and market access can pose challenges for pharmaceutical companies aiming to bring new therapies to market. The potential for stringent regulations and lengthy approval processes may hinder innovation and delay patient access to essential treatments.

Additionally, competition within the pharmaceutical sector is intensifying, with numerous companies vying to establish their presence in the ovarian cancer drugs market. The rapid pace of innovation can lead to an oversaturated market, potentially resulting in price wars and reduced profit margins for companies. The emergence of alternative therapies, including natural and holistic approaches, may also divert patient attention and resources away from conventional pharmaceutical treatments. Furthermore, changes in healthcare policies and reimbursement models may affect the overall profitability and sustainability of drug development initiatives, adding another layer of complexity for companies operating within this landscape.

Competitor Outlook

• Roche Holding AG
• Merck & Co., Inc.
• GlaxoSmithKline plc
• Pfizer Inc.
• Bristol-Myers Squibb Company
• AstraZeneca plc
• Johnson & Johnson
• Novartis AG
• Amgen Inc.
• Tesaro, Inc. (part of GlaxoSmithKline)
• Clovis Oncology, Inc.
• AbbVie Inc.
• Regeneron Pharmaceuticals, Inc.
• OncoMed Pharmaceuticals, Inc.
• Janssen Pharmaceuticals, Inc.

The competitive landscape of the ovarian cancer drugs market is characterized by the presence of several major pharmaceutical companies that are actively engaged in the research, development, and commercialization of innovative therapies. These companies are continually vying for market share through the introduction of novel products and strategic collaborations aimed at enhancing treatment options for ovarian cancer. With a focus on precision medicine, many of these firms are investing heavily in clinical trials to establish the safety and efficacy of new drug candidates. The market is also seeing an influx of smaller biotech firms that are harnessing cutting-edge technology and research to develop therapies targeting specific genetic mutations associated with ovarian cancer, thereby intensifying the competition.

Among the key players, Roche Holding AG and Merck & Co., Inc. are leading the charge with their robust portfolios of cancer therapies, including immunotherapies and targeted agents. Roche's approval of atezolizumab for ovarian cancer has provided a significant boost to its market position, while Merck's pembrolizumab continues to gain traction as an effective immunotherapy option. Pfizer Inc. is another notable competitor, leveraging its strong presence in oncology to expand its offerings and explore combination therapies that enhance treatment regimens. Additionally, AstraZeneca and Bristol-Myers Squibb are making substantial strides in the ovarian cancer space, focusing on both drug development and partnership collaborations to accelerate their pipeline of therapies.

As the market evolves, it is anticipated that mergers, acquisitions, and partnerships will become more prevalent as companies seek to strengthen their market position and expand their therapeutic offerings. For instance, the acquisition of Tesaro, Inc. by GlaxoSmithKline underscores the growing interest in the ovarian cancer segment and the need for companies to diversify their portfolios. Meanwhile, Clovis Oncology, known for its focus on PARP inhibitors, represents the innovative spirit driving the competitive landscape as it seeks to carve its niche within the market. Overall, the dynamic nature of the ovarian cancer drugs market, combined with ongoing research and clinical advancements, ensures that the competition will remain fierce and the landscape continually evolving.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 AbbVie Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Novartis AG
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Pfizer Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 AstraZeneca plc
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Roche Holding AG
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Johnson & Johnson
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Merck & Co., Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 GlaxoSmithKline plc
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Clovis Oncology, Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Bristol-Myers Squibb Company
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Janssen Pharmaceuticals, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 OncoMed Pharmaceuticals, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Regeneron Pharmaceuticals, Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Tesaro, Inc. (part of GlaxoSmithKline)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Ovarian Cancer Drugs Market, By Drug Class
    • 6.1.1 Platinum-Based Drugs
    • 6.1.2 PARP Inhibitors
    • 6.1.3 Angiogenesis Inhibitors
    • 6.1.4 PD-L1 Inhibitors
    • 6.1.5 Others
  • 6.2 Ovarian Cancer Drugs Market, By Administration
    • 6.2.1 Oral
    • 6.2.2 Injectable
  • 6.3 Ovarian Cancer Drugs Market, By Distribution Channel
    • 6.3.1 Hospitals
    • 6.3.2 Cancer Treatment Centers
    • 6.3.3 Retail Pharmacies
    • 6.3.4 Online Pharmacies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Ovarian Cancer Drugs Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Ovarian Cancer Drugs market is categorized based on

By Drug Class

• Platinum-Based Drugs
• PARP Inhibitors
• Angiogenesis Inhibitors
• PD-L1 Inhibitors
• Others

By Administration

• Oral
• Injectable

By Distribution Channel

• Hospitals
• Cancer Treatment Centers
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Roche Holding AG
• Merck & Co., Inc.
• GlaxoSmithKline plc
• Pfizer Inc.
• Bristol-Myers Squibb Company
• AstraZeneca plc
• Johnson & Johnson
• Novartis AG
• Amgen Inc.
• Tesaro, Inc. (part of GlaxoSmithKline)
• Clovis Oncology, Inc.
• AbbVie Inc.
• Regeneron Pharmaceuticals, Inc.
• OncoMed Pharmaceuticals, Inc.
• Janssen Pharmaceuticals, Inc.